Literature DB >> 17599723

Involuntary emotional expressive disorder: a case for a deeper neuroethics.

Peter J Whitehouse1, Sara Waller.   

Abstract

Understanding why we produce labels for neuropsychiatric conditions, such as Alzheimer's disease (AD), and how we use those words to tell stories about our brain, as well as which groups control such diagnostic discourse, is important to a wise understanding of our cognitive abilities, their limitations, and even our very human nature. Here, we explore the history and current focus of a newly emerging field called neuroethics and explore its relationship (or lack thereof) to a newly created clinical syndrome called involuntary emotional expressive disorder (IEED). The main argument concerns the lack of neuroethical discussion of issues pertinent to social influences on disease and the construction of professional specialization. We are critical of the processes associated with the creation of both the field and the syndrome, and express concern about their eventual outcomes. The interaction of social, political, and business institutions, the inherent interests of the advancement of larger research projects (and the individuals that compose them), their potential for profit, and other incentives to enhance marketability and public attention toward certain research programs will be examined as we discuss the development of the field of neuroethics. Similarly, we argue that these social factors and forces are instrumental in the development of IEED as a recognizable category and condition. Our critique is guided by the hope that through such analyses we can improve our understanding of how we go about our academic activities in cognitive neuroscience and also improve our efforts to help people suffering from neuropsychiatric conditions, such as dementia.

Entities:  

Mesh:

Year:  2007        PMID: 17599723     DOI: 10.1016/j.nurt.2007.03.003

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  15 in total

1.  The end of Alzheimer disease.

Authors:  P J Whitehouse
Journal:  Alzheimer Dis Assoc Disord       Date:  2001 Apr-Jun       Impact factor: 2.703

2.  Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.

Authors:  Hillel S Panitch; Ronald A Thisted; Richard A Smith; Daniel R Wynn; James P Wymer; Anat Achiron; Timothy L Vollmer; Raul N Mandler; Dennis W Dietrich; Malcolm Fletcher; Laura E Pope; James E Berg; Ariel Miller
Journal:  Ann Neurol       Date:  2006-05       Impact factor: 10.422

3.  Van Rensselaer Potter: an intellectual memoir.

Authors:  Peter J Whitehouse
Journal:  Camb Q Healthc Ethics       Date:  2002       Impact factor: 1.284

4.  Defining and diagnosing involuntary emotional expression disorder.

Authors:  Jeffrey L Cummings; David B Arciniegas; Benjamin R Brooks; Robert M Herndon; Edward C Lauterbach; Erik P Pioro; Robert G Robinson; Douglas W Scharre; Randolph B Schiffer; Daniel Weintraub
Journal:  CNS Spectr       Date:  2006-06       Impact factor: 3.790

Review 5.  The differential diagnosis of pseudobulbar affect (PBA). Distinguishing PBA among disorders of mood and affect. Proceedings of a roundtable meeting.

Authors:  David B Arciniegas; Edward C Lauterbach; Karen E Anderson; Tiffany W Chow; Laura A Flashman; Robin A Hurley; Daniel I Kaufer; Thomas W McAllister; Alison Reeve; Randolph B Schiffer; Jonathan M Silver
Journal:  CNS Spectr       Date:  2005-05       Impact factor: 3.790

6.  An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde".

Authors:  A Alzheimer; R A Stelzmann; H N Schnitzlein; F R Murtagh
Journal:  Clin Anat       Date:  1995       Impact factor: 2.414

7.  Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.

Authors:  B R Brooks; R A Thisted; S H Appel; W G Bradley; R K Olney; J E Berg; L E Pope; R A Smith
Journal:  Neurology       Date:  2004-10-26       Impact factor: 9.910

Review 8.  Antiaging medicine and mild cognitive impairment: practice and policy issues for geriatrics.

Authors:  Peter J Whitehouse; Eric T Juengst
Journal:  J Am Geriatr Soc       Date:  2005-08       Impact factor: 5.562

9.  Teaching bioethics in the new millennium: holding theories accountable to actual practices and real people.

Authors:  Rosemarie Tong
Journal:  J Med Philos       Date:  2002-08

10.  Prevalence and clinical correlates of pathological affective display in Alzheimer's disease.

Authors:  S E Starkstein; R Migliorelli; A Tesón; G Petracca; E Chemerinsky; F Manes; R Leiguarda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-07       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.